Ubs Group Ag Atossa Therapeutics, Inc. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 260,722 shares of ATOS stock, worth $211,184. This represents 0.0% of its overall portfolio holdings.

Number of Shares

260,722

Previous 412,462 36.79%

Holding current value

$211,184

Previous $342,000 34.5%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$0.74 - $0.97 $112,287 - $147,187	-151,740 Reduced 36.79%	260,722 $224,000
Q2 2025 Aug 14, 2025	SELL	$0.59 - $1.03 $25,325 - $44,211	-42,924 Reduced 9.43%	412,462 $342,000
Q1 2025 May 13, 2025	SELL	$0.67 - $1.01 $448,442 - $676,010	-669,317 Reduced 59.51%	455,386 $305,000
Q4 2024 Feb 14, 2025	BUY	$0.94 - $1.62 $990,675 - $1.71 Million	1,053,910 Added 1488.72%	1,124,703 $1.06 Million
Q3 2024 Nov 14, 2024	BUY	$1.09 - $1.52 $31,982 - $44,599	29,342 Added 70.79%	70,793 $107,000

Q2 2024 Aug 13, 2024	BUY	$1.03 - $2.1 $42,258 - $86,158	41,028 Added 9699.29%	41,451 $49,000
Q1 2024 May 13, 2024	BUY	$0.8 - $1.89 $314 - $742	393 Added 1310.0%	423 $0
Q4 2023 Feb 09, 2024	SELL	$0.63 - $0.98 $20,997 - $32,662	-33,329 Reduced 99.91%	30 $0
Q3 2023 Nov 09, 2023	BUY	$0.74 - $1.35 $24,685 - $45,034	33,359 New	33,359 $24,000
Q3 2022 Nov 10, 2022	SELL	$0.82 - $1.14 $4,455 - $6,194	-5,434 Reduced 93.8%	359 $0
Q2 2022 Aug 10, 2022	SELL	$0.85 - $1.28 $25,751 - $38,778	-30,296 Reduced 83.95%	5,793 $6,000
Q1 2022 May 16, 2022	SELL	$1.11 - $1.74 $40,772 - $63,913	-36,732 Reduced 50.44%	36,089 $45,000
Q4 2021 Feb 14, 2022	BUY	$1.6 - $3.27 $51,449 - $105,150	32,156 Added 79.08%	72,821 $117,000
Q3 2021 Nov 15, 2021	BUY	$2.89 - $6.4 $117,521 - $260,256	40,665 New	40,665 $133,000
Q2 2021 Aug 13, 2021	SELL	$1.52 - $8.62 $39,778 - $225,585	-26,170 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$0.92 - $4.33 $24,076 - $113,316	26,170 New	26,170 $55,000
Q4 2020 Feb 11, 2021	SELL	$0.85 - $2.43 $3,276 - $9,367	-3,855 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$1.98 - $4.35 $4,488 - $9,861	2,267 Added 142.76%	3,855 $9,000
Q2 2020 Jul 31, 2020	BUY	$1.04 - $4.05 $1,651 - $6,431	1,588 New	1,588 $6,000
Q1 2020 May 01, 2020	SELL	$0.79 - $1.62 $4,736 - $9,711	-5,995 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.25 - $1.87 $5,735 - $8,579	4,588 Added 326.08%	5,995 $9,000
Q3 2019 Nov 14, 2019	BUY	$1.96 - $2.52 $2,757 - $3,545	1,407 New	1,407 $3,000
Q1 2019 May 14, 2019	SELL	$1.11 - $7.07 $5,278 - $33,617	-4,755 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$0.92 - $1.67 $4,374 - $7,940	4,755 New	4,755 $5,000
Q3 2018 Nov 14, 2018	SELL	$1.47 - $2.78 $13,418 - $25,375	-9,128 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.2 - $5.28 $20,081 - $48,195	9,128 New	9,128 $20,000

Others Institutions Holding ATOS

# of Institutions

Shares Held

26.8M

Call Options Held

79.5K

Put Options Held

98.8K

View Full List

About ATOSSA THERAPEUTICS, INC.

Ticker ATOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,624,000
Market Cap $103M
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...

More about ATOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account